Transcriptionally induced enhancers in the macrophage immune response to Mycobacterium tuberculosis infection by Denisenko, Elena et al.
RESEARCH ARTICLE Open Access
Transcriptionally induced enhancers in
the macrophage immune response to
Mycobacterium tuberculosis infection
Elena Denisenko1, Reto Guler2,3, Musa Mhlanga4,5,6, Harukazu Suzuki7, Frank Brombacher2,3 and
Sebastian Schmeier1*
Abstract
Background: Tuberculosis is a life-threatening infectious disease caused by Mycobacterium tuberculosis (M.tb). M.tb
subverts host immune responses to build a favourable niche and survive inside of host macrophages. Macrophages
can control or eliminate the infection, if acquire appropriate functional phenotypes. Transcriptional regulation is a
key process that governs the activation and maintenance of these phenotypes. Among the factors orchestrating
transcriptional regulation during M.tb infection, transcriptional enhancers still remain unexplored.
Results: We analysed transcribed enhancers in M.tb-infected mouse bone marrow-derived macrophages. We
established a link between known M.tb-responsive transcription factors and transcriptional activation of
enhancers and their target genes. Our data suggest that enhancers might drive macrophage response via
transcriptional activation of key immune genes, such as Tnf, Tnfrsf1b, Irg1, Hilpda, Ccl3, and Ccl4. We report
enhancers acquiring transcription de novo upon infection. Finally, we link highly transcriptionally induced
enhancers to activation of genes with previously unappreciated roles in M.tb infection, such as Fbxl3, Tapt1,
Edn1, and Hivep1.
Conclusions: Our findings suggest the importance of macrophage host transcriptional enhancers during M.tb
infection. Our study extends current knowledge of the regulation of macrophage responses to M.tb infection
and provides a basis for future functional studies on enhancer-gene interactions in this process.
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Background
Tuberculosis (TB) remains a significant global threat,
which causes over one million deaths each year. The
causative agent of TB is Mycobacterium tuberculosis
(M.tb), an intracellular pathogen that mainly persists in-
side host macrophages [1]. Over 30% of the world’s
population is infected with M.tb, and the infection pro-
gresses to active TB in about 5–10% of cases [1, 2]. Mac-
rophages are one of the first lines of a host’s defence
against invading bacterial pathogens [3]. The complex
interplay between host macrophages and M.tb is be-
lieved to be central to the control of infection and
defines the infection outcome [4, 5]. Macrophages are
equipped with a multitude of strategies to combat M.tb,
however, the pathogen has developed a wide range of
matching resistance mechanisms, allowing it to avoid
destruction and to survive and proliferate inside macro-
phages [5]. Hence, macrophage responses need to be
tightly controlled in order to eliminate the pathogen.
The lack of effective TB control systems is in part ex-
plained by significant gaps in our knowledge of the biology
of M.tb and its interactions with the host [4]. Conse-
quently, understanding the cellular pathways that underlie
the initial infection and TB progression remains a scien-
tific challenge directly applicable to human health.
Gene expression in eukaryotic cells is a complex
process guided by a multitude of mechanisms [6]. Regu-
lation of transcription represents one of the first layers
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of gene expression control, which largely defines rapid
signal-dependent expression changes [7]. Enhancers
are defined as cis-regulatory DNA regions that acti-
vate transcription of target genes in a distance- and
orientation-independent manner [8]. Nowadays, en-
hancers are considered major determinants of gene
expression programmes required for establishing
cell-type specificity and mediating responses to extra-
cellular signals [9–11].
Enhancers are characterised by a set of distinctive fea-
tures. Genomic regions surrounding enhancers carry a
combination of H3K4me1 and H3K27ac histone marks
that has been considered an enhancer-specific chromatin
signature [12, 13]. H3K4me1 demarcates established or
primed enhancers, which may or may not be active,
while a combination of H3K4me1 and H3K27ac marks
active enhancers [12, 13]. Enhancer regions carry mul-
tiple DNA binding sites and can recruit transcription
factors and coactivators, RNA polymerase II and other
proteins, such as histone acetyltransferases [9, 14, 15].
Enhancers serve as a platform for assembly of the tran-
scription pre-initiation complex, which can result in en-
hancer regions being transcribed into non-coding
enhancer RNAs termed eRNAs [14, 15]. This novel class
of RNAs was first introduced in a genome-wide study in
mouse neurons [16]. Later on, a number of studies
showed that the production of eRNAs correlated with
target mRNA synthesis and eRNAs could serve as robust
and independent indicators of active enhancers, that are
more likely to be validated in vitro [17–21]. Detect-
able eRNA levels are usually low, possibly due to
their short half-life and fast degradation by RNA exo-
somes or their generally low transcription initiation
rates [11, 22–24]. Nevertheless, eRNA transcription
can be used for a genome-wide identification of active
enhancers [17, 25, 26].
The dominant model of transcriptional regulation by
enhancers states that it is exerted via direct physical inter-
action between an enhancer and a target gene promoter,
mediated by DNA looping [8]. Topologically associating
domains (TADs) have emerged as critical conserved units
of chromatin organisation that favour internal DNA con-
tacts, whereas regulatory interactions between TADs are
limited [27, 28]. Enhancer-promoter contacts are believed
to occur almost exclusively within the well-conserved
TADs [29]. Notably, enhancer-promoter interactions are
not limited to one-to-one contacts. Instead, an enhancer
might regulate a few genes, and multiple enhancers might
contribute to the activation of a gene [30]. Such enhancer
redundancy was recently shown to confer phenotypic
robustness to loss-of-function mutations in individual en-
hancers [31]. Both enhancers and enhancer-gene regula-
tory interactions are characterised by a remarkable tissue
specificity [13, 18, 20]. Such tissue specificity is crucial for
establishing cell-type- and state-specific transcriptional
programmes [9, 10]. Moreover, enhancer-gene interac-
tions can be dynamically rewired in response to environ-
mental stimuli, enabling fine tuning of gene expression
programmes [19, 32].
Previously we used cap analysis of gene expression
(CAGE) and epigenetic data to identify on large-scale
transcribed enhancers (i.e. enhancers producing eRNAs)
in bone marrow-derived mouse macrophages (BMDM)
[33]. We have established a transcribed enhancer and
target gene interactome and characterised the roles of
enhancers in guiding macrophage polarisation into dis-
tinct pro- and anti-inflammatory phenotypes [33]. Here,
we extended the former study to conduct the first to our
knowledge genome-wide analysis of transcribed en-
hancers guiding BMDM response to M.tb infection. Our
findings indicate that transcribed enhancers are exten-
sively involved in the induction of immune genes during
M.tb infection. We identify and characterise enhancers
with induced or de novo acquired eRNA expression and
transcription factors that likely drive these changes. We
report enhancer regions that target known immune
genes crucial for the host response to M.tb. These find-
ings are extended by highlighting genes with previously
unappreciated roles in M.tb infection, as their regulation
by many enhancers points to their functional import-
ance. Taken together, our findings extend the current
knowledge of M.tb-induced immune response regulation
in macrophages and provide a basis for future functional
studies on enhancer-gene interactions in this process.
Results
Transcribed enhancers in macrophage responses to M.tb
infection
We analysed the host transcriptional response to M.tb
infection in mouse bone marrow-derived macrophages
(BMDM) at 4, 12, 24, and 48 h post infection (see
Methods). Non-infected control BMDM were profiled
prior to infection (0 h) and at matched time points (4,
12, 24 and 48 h). First, we analysed overall gene expres-
sion changes and found that they were the strongest at
4 h post infection and declined with time (Fig. 1a-c).
Half as many differentially expressed genes (DEGs) were
detected at 12 h as at 4 h, and almost no genes were sig-
nificantly differentially expressed at 24 or 48 h post in-
fection (see Methods, Fig. 1a). We combined the DEGs
from all time points into two unique lists of 1384 up-
and 1604 down-regulated DEGs for further analysis.
We have previously identified 8667 actively transcribed
enhancers and their target genes in mouse BMDM [33].
Here, we found that many of these enhancers acquired
higher eRNA expression in response to M.tb infection
(Additional file 1: Figure S1a). Moreover, enhancers asso-
ciated with up-regulated DEGs in infected macrophages
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showed an increase in eRNA expression (Additional file 1:
Figure S1b, see Methods and Additional file 2: Table S1
for the list of up-regulated DEGs and their enhancers).
Hence, BMDM enhancers showed an overall increase in
transcriptional activity upon M.tb infection.
We investigated the differences in the enhancer rep-
ertoire between DEGs and non-DEGs to uncover the
role of enhancers in the M.tb infection response.
Genes with no transcribed enhancers composed 36.4%
of up-regulated DEGs, whereas this percentage was
significantly higher at 41.1% for down-regulated DEGs
(Fisher’s exact test two-sided p-value 0.008) (Fig. 1d).
Furthermore, 41% of up-regulated DEGs, but only
34% of down-regulated DEGs were associated with
more than two transcribed enhancers (Fisher’s exact
test two-sided p-value 7.9*10− 05) (Fig. 1d). Finally,
non-DEGs had the highest percentage of genes with
no transcribed enhancers (45%) and the lowest per-
centage of genes with more than two enhancers (31%)
(Fig. 1d). Hence, transcribed enhancers likely play a
prominent role in up-regulation of protein-coding
genes in the response to M.tb infection.
Previously we have shown that regulation of genes by
many transcribed enhancers in BMDM was a concomitant
of higher gene expression and tissue-specific function
[33]. Here, we asked whether the same properties could
be observed for up-regulated DEGs, as genes most likely
to be involved in the elimination of M.tb. Indeed, as be-
fore, we noted higher expression levels in genes associated
with more enhancers in M.tb-infected macrophages (Fig.
1e). Gene set enrichment analysis (GSEA, see Methods)
showed that DEGs with no transcribed enhancers in
M.tb-infected macrophages were only significantly
enriched (FDR < 0.05) in five KEGG pathway maps (Fig.
1f). In contrast, genes associated with more than two en-
hancers were significantly enriched in as many as 92 path-
way maps (S2 Table), and showed a much stronger
enrichment for more specific infection-related pathways
(Fig. 1g, Additional file 3: Table S2) when compared to
genes with no enhancers (Fig. 1f). The enrichment ana-
lysis points to the assumption that up-regulated DEGs
without transcribed enhancers are functionally less related
than those associated with more than two actively tran-
scribed enhancers. Moreover, these results indicate that
even within such a process-oriented set as the list of
up-regulated DEGs, multiple enhancers might regulate
the most highly expressed and functionally important
genes. We repeated this analysis for all genes (as op-
posed to only DEGs) and their associated enhancers in
infected macrophages and observed a similar trend
Fig. 1 Enhancers mediate up-regulation of immune genes in macrophages upon M.tb infection. a Numbers of differentially expressed genes
(DEGs) in infected macrophages vs. macrophages prior to the infection (0 h). b Expression of 1384 up-regulated DEGs. c Expression of 1604
down-regulated DEGs. In (b) and (c), genes are differentially expressed at any time point; expression in TPM was averaged across replicates;
dashed lines show median gene expression prior to the infection. d Percentage of genes associated with different number of enhancers in
infected macrophages; numbers indicate Fisher’s exact test p-values. e Expression of genes associated with different number of enhancers in
infected macrophages; expression in TPM was averaged across infected samples, dashed lines show the median expression of genes not
associated with any transcribed enhancer; numbers indicate Wilcoxon two-sided rank sum test p-values. f KEGG pathway maps significantly
enriched for up-regulated DEGs with no associated transcribed enhancers, FDR < 0.05. g Top 10 KEGG pathway maps with the lowest FDR
enriched for up-regulated DEGs associated with more than two transcribed enhancers. In (f) and (g), next to the bars are the numbers of genes
in the KEGG term covered by our gene list; dashed lines indicate FDR = 0.05
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(Additional file 4: Figure S2), in agreement with our
previous study [33].
We next compared our transcribed enhancers to a set
of inflammation-sensitive LPS-responsive macrophage
super enhancers (SEs) reported by Hah et al. [34].
Super-enhancers (or stretch enhancers) have emerged as
a sub-class of particularly potent enhancers, which are
associated with higher levels of enhancer-specific histone
marks and regulate key cell identity genes [35, 36].
Among 2999 enhancers associated with up-regulated
DEGs, 45.9% overlapped SE regions. This percentage
was significantly lower at 30% for the remainder of our
BMDM transcribed enhancers [33] (two-sided Fisher’s
exact test p-value < 2.2*10− 16, odds ratio 1.98). Interest-
ingly, of 880 up-regulated DEG associated with tran-
scribed enhancers, 477 were associated with enhancers
overlapping SEs, and these DEGs showed a much stronger
enrichment for immune-related functions, when com-
pared to the 403 DEGs for which none of their associated
enhancers overlapped SEs (Additional file 5: Figure S3).
Taken together, our findings indicate that the
up-regulation of immune genes in BMDM upon M.tb in-
fection might be largely driven by transcribed enhancers.
Comparison of the three subsets of up-regulated DEGs
showed the strongest enrichment for specific immune re-
sponse pathways in up-regulated DEGs associated with
SEs (Additional file 5: Figure S3b) and the weakest enrich-
ment in up-regulated DEGs not associated with any tran-
scribed enhancers (Fig. 1f), highlighting the functional
importance of SEs in BMDM response to M.tb infection.
Transcriptionally induced enhancer regulation of immune
genes during M.tb infection
We further set out to investigate a subset of enhancers
that targeted up-regulated DEGs and were themselves
highly transcriptionally induced upon infection. We fo-
cused on 809 DEGs that were associated to transcribed
enhancers and up-regulated at 4 h post infection, as we
observed the strongest transcriptional response upon in-
fection at this time point. Of enhancers targeting these
DEGs, we selected those with the highest eRNA expres-
sion at 4 h and its fold change as compared to 0 h, by
requiring both these values to be in the upper quartiles
of their corresponding distributions (see Methods). The
derived set of 257 enhancers (further referred to as
induced enhancers) was associated with 263 of 809
DEGs that were up-regulated at 4 h and associated with
transcribed enhancers (Additional file 6: Figure S4,
Additional file 7: Table S3). We investigated expression
of the induced enhancers in other mouse tissues
(Additional file 8: Table S4). Interestingly, we found that
the set of enhancers showed the highest average and
maximum eRNA expression, as well as the highest per-
centage of samples with nonzero eRNA expression in
infected macrophages (Additional file 9: Figure S5). In
addition, induced enhancers were over-represented in
SE regions [34] when compared to the remainder of
BMDM enhancers, with 60.7% of the induced en-
hancers overlapping SEs as compared to 34.7% of
non-induced enhancers (two-sided Fisher’s exact test
p-value < 2.2*10− 16, odds ratio 2.9). These findings in-
dicate a high specificity of the induced enhancers to the
BMDM infection response and highlight the fact that
they are likely key elements for driving the transcrip-
tional responses of the macrophage upon infection.
Next, we investigated DEGs that were targeted by
many induced enhancers as it stands to reason that
these genes play crucial parts in the response to M.tb.
Among the 263 DEGs, Tumour necrosis factor receptor
2 (Tnfrsf1b) was associated with the highest number of
the induced enhancers, eight (Fig. 2). Interestingly, one
of the induced enhancers (chr4:145245568..145245969,
Fig. 2b) showed the second highest mean eRNA expres-
sion (28.79 TPM) at 4 h post infection among all en-
hancers targeting up-regulated DEGs. Tumour necrosis
factor (Tnf ), coding a ligand of Tnfrsf1b, was associated
with three induced enhancers with mean eRNA expres-
sion of 2.4, 3.9, and 10.8 TPM at 4 h post infection. We
found that induced enhancers associated with Tnfrsf1b
were significantly over-represented in the corresponding
TAD (eight induced enhancers among 38 BMDM en-
hancers in the TAD, hypergeometric test FDR = 0.005,
see Methods). Interestingly, Tnfrsf1b was the only
up-regulated DEG within the TAD (log2FC = 2.2 at 4 h
vs. 0 h, Fig. 2a) and encodes the Tnf receptor 2, which is
known to interfere with apoptosis [37] and sensitize
macrophages for Tnfr1-mediated necroptosis, a pro-
grammed form of inflammatory cell death resulting from
cellular damage or infiltration by pathogens [38]. Given
that all of Tnfrsf1b’s induced enhancers coincide with a
SE, we hypothesise that the activation of the SE upon in-
fection is driving the process in conjunction with in-
creased eRNA expression from the induced enhancers.
Another TAD on chromosome 14 contained a group
of three co-regulated DEGs (Irg1, Cln5, and Fbxl3)
associated with six induced enhancers each, the second
highest number after Tnfrsf1b reported above (Add-
itional file 10: Figure S6). Moreover, among these six,
the chr14:103037012..103037413 enhancer showed the
highest mean eRNA expression (36.68 TPM) at 4 h post
infection among all enhancers of up-regulated DEGs
(Additional file 10: Figure S6b, enhancer e2). Finally, six
out of 14 enhancers in the TAD were deemed induced
enhancers (significant over-representation with hyper-
geometric test FDR = 0.001, see Methods). Of the three
DEGs, Irg1 showed the strongest induction of log2FC =
5.2 at 4 h vs. 0 h (Additional file 10: Figure S6a). Irg1 was
recently shown to link cellular metabolism with immune
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defence by catalysing the production of itaconic acid,
which has antimicrobial activity and inhibits the growth of
M.tb [39]. Another gene in this TAD encodes Cln5
(log2FC = 2), which is required to recruit and activate
Rab7 [40], a GTPase essential for phagosome maturation,
a process which is crucial for microbial killing by macro-
phages and which can be disrupted by M.tb as a part of its
survival strategy [41–43]. The link between highly induced
enhancers and Irg1 and Cln5 points to biological processes
important for the host response that might be driven by
transcribed enhancers, while the immune functions of
Fbxl3 (log2FC = 1.4) are yet to be elucidated.
Induced enhancers were significantly over-represented
with FDR < 0.05 in four more TADs, which we further
investigated as potentially important M.tb-responsive
genomic regions (Additional file 11: Table S5). One of
the TADs (FDR = 0.001, five induced enhancers among
eight BMDM transcribed enhancers, Additional file 12:
Figure S7) is as large as 1.2Mb and contains multiple
genes, however, only Hilpda (Hig2) was differentially
expressed and up-regulated at 4 h (log2FC = 6,
Additional file 12: Figure S7a). Hilpda is induced in hyp-
oxia and is crucial to lipid accumulation in macrophages
[44], which provides a favourable environment for
Fig. 2 Regulation of Tnfrsf1b by induced enhancers. a Time course expression of the Tnfrsf1b gene. b Time course eRNA expression of Tnfrsf1b-
associated induced enhancer. In (a) and (b), data were averaged over replicates and log-transformed, error bars are the SEM (see Methods). c
TAD containing Tnfrsf1b and associated enhancers; induced enhancers are shown as longer green blocks. Genes are split into two tracks based
on the strand, wide orange marks denote gene promoters. DEGs significantly up-regulated at 4 h are shown in purple and their associations with
enhancers are shown as thicker black connections. Super enhancers are shown as defined by Hah et al. [34] in LPS-treated macrophages. Histone
marks are shown as defined by Ostuni et al. [61] in untreated and LPS-treated macrophages
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dormant M.tb and might, thus, contribute to M.tb sur-
vival within the host [45]. Similarly, Itgb8 was the only
up-regulated DEG (log2FC = 7.1) in another TAD with
five induced enhancers among 14 BMDM transcribed
enhancers (FDR 0.011, Additional file 13: Figure S8). Al-
though specific roles of Itgb8 in M.tb infection response
have not yet been established, integrin alpha(v)beta8 is
known to activate TGF-beta [46], an important mediator
of susceptibility to M.tb [47].
A TAD with four induced enhancers among eight
BMDM transcribed enhancers (FDR = 0.012) contains
three DEGs up-regulated at 4 h post infection (Add-
itional file 14: Figure S9). Cd38 and Bst1 (Cd157) are
homologous NAD(+) metabolic enzymes up-regulated
by Tnf [48], and Cd38 was shown to be involved in
phagocytosis [49] and response to intracellular pathogen
Listeria monocytogenes [50] in mouse macrophages. The
role of the third gene in that TAD, transmembrane pro-
tein Tapt1, remains to be elucidated.
Finally, a TAD with five induced enhancers among 17
BMDM transcribed enhancers (FDR = 0.02) covers four
DEGs Ccl3, Ccl4, Ccl9, and Wfdc17 (Additional file 15:
Figure S10). Ccl3 and Ccl4 are macrophage-derived in-
flammatory chemokines that induce chemotactic
mobilization of immune cells [51], while Wfdc17 might
have the opposite function decreasing production of
pro-inflammatory cytokines [52], and the function of
Ccl9 in macrophage infection response remains to be
uncovered [51].
Taken together, these examples highlight six TADs
(Additional file 11: Table S5), located on six different
chromosomes, which show strong responses to M.tb in-
fection and contain genes with both known and previ-
ously unappreciated roles in M.tb infection. These genes
are under the control of multiple M.tb induced en-
hancers, which might be essential for contributing to the
genes’ activation states.
To get further insights into the capacity of induced en-
hancer regulation during the response to M.tb infection,
we investigated target DEGs of induced enhancers that
were significantly enriched in particular biological path-
ways (Additional file 6: Figure S4b). The Tnf signalling
pathway showed the strongest enrichment for induced
enhancer-regulated DEGs and included 18 DEGs
up-regulated at 4 h and associated with the induced en-
hancers. Among these genes, in addition to Tnfrsf1b re-
ported above, we identified Tnf itself, Tnf signalling
pathway mediator Traf5 and multiple effector genes tar-
geted by induced enhancers (Additional file 16: Table
S6). Tnf-alpha receptors are known to trigger the NF-kB
signalling pathway, which was also enriched for DEGs
regulated by induced enhancers, including receptors
Cd14 and Cd40, ligand Il1b, and TFs of canonical NF-kB
signalling, Nfkb1 and Rela (Additional file 16: Table S6).
‘Tuberculosis’ KEGG pathway map comprised five signal
transduction mediators, Irak2, Jak2, Malt1, Ripk2, and
Src, regulated by induced enhancers (Additional file 16:
Table S6). In addition, induced enhancers target the
Eea1 gene, which is known to be involved in phagosome
maturation, a process necessary for killing of bacteria
within phagosomes [53] (Additional file 16: Table S6).
Notably, genes encoding negative regulators of the listed
signalling pathways, Nfkbia, Tnfaip3, and Socs3, were
also associated with one to five induced enhancers
(Additional file 16: Table S6), and showed up-regulation.
Transcriptionally induced enhancers are enriched for
immune transcription factor binding sites
Transcription factor (TF) binding motif analysis was
performed to uncover TFs potentially involved in the
transcriptional activation of induced enhancers. We
identified twelve significantly over-represented motifs of
TFs that were differentially expressed and up-regulated
at 4 h post infection (see Methods, Table 1). Five of these
motifs belong to the AP-1 family of TFs, among which
the highest expressed one was Junb, recently reported to
be an important regulator of immune genes in macro-
phages treated with LPS [54]. Interestingly, a negative
regulator of AP-1, Jdp2, was also among the significantly
over-represented motifs, although it was found only in
20.6% of the induced enhancers. Three motifs of NF-kB
family were identified, among which Rela was reported
above to be itself regulated by the induced enhancers,
potentially forming a positive feedback loop. For another
TF identified here, Irf1, we have previously reported that
in association with Batf2 (log2FC = 2.7) it induced in-
flammatory responses in M.tb infection [55]. Both AP-1
and NF-kB families of TFs, as well as Irf1, play import-
ant roles in macrophages and can be triggered by a
range of infection response receptors including Toll-like
and Nod-like receptors [56, 57]. Rbpj, which showed the
second strongest motif over-representation, is a key TF
of canonical Notch signalling pathway, which is known
to be activated by Toll-like receptor signalling pathways
[58]. Finally, Nfe2l2 (Nrf2) regulates cytoprotective genes
that enhance cell survival and was shown to increase
phagocytic ability of macrophages and to improve anti-
bacterial defence [59, 60].
Importantly, 89.1% of the 257 induced enhancers con-
sidered here carry at least one of the twelve motifs, and
these enhancers target 95.1% of the 263 up-regulated
DEGs (Table 2). Among the motifs, AP-1 family mem-
bers covered the largest percentages of the induced en-
hancers and their target genes, followed by the NF-kB
family and Rbpj TF, highlighting their importance in en-
hancer regulation of M.tb response. We compared this
TF regulation of protein-coding genes via enhancers to
TFs that bind directly to the promoters of the 263
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up-regulated DEGs (see Methods). In the promoters,
Irf1, as well as AP-1, and NF-kB families were similarly
significantly over-represented, whereas, Rbpj, Nfe2l2 and
Jdp2 were not deemed significant and, thus, might be
specific to the transcriptionally induced enhancers.
Taken together, these findings link M.tb-perturbed sig-
nalling pathways and their key TFs to transcriptional ac-
tivation of the induced enhancers, which in turn activate
their immune target DEGs.
A subset of enhancers is transcribed de novo upon M.tb
infection
Interestingly, among 257 induced enhancers we found
17 enhancers that showed zero eRNA expression in all
of the 22 non-infected macrophage samples. Hence,
transcription of these enhancers was specifically ac-
quired de novo in macrophages upon M.tb infection.
These enhancers were associated with 31 of the 263
DEGs under investigation, which included Hilpda, Il1b,
Itgb8, Jak2, Src, and Tnfaip3 genes, reported above. We
set out to further investigate in more detail the
phenomenon of de novo transcription at enhancers.
We focused on enhancers that were transcriptionally
silent in naïve BMDM, but acquired transcriptional ac-
tivity de novo in M.tb-infected macrophages (further re-
ferred to as acquired enhancers). We hypothesized that
such enhancers might either loop towards their target
promoters in non-infected macrophages without being
transcriptionally active, or form a novel DNA loop upon
infection (Fig. 3a-b). In total, we identified 356 acquired
enhancers (see Methods). Their eRNA expression was
the highest at 4 and 12 h post infection and declined
with time (Fig. 3c, left panel), in agreement with the
DEG expression reported above. Notably, overall expres-
sion of acquired enhancers in infected macrophages was
lower than that of induced enhancers (median of 0.23
TPM versus 1.73 TPM at 4 h). However, similarly to in-
duced enhancers, acquired enhancers showed the high-
est expression in infected macrophages when compared
to other mouse tissues (Additional file 17: Figure S11).
Thus, the transcriptional activity of acquired enhancers
Table 1 TF motifs over-represented in the induced enhancers
TF Motif # overlapping enhancers Expression, TPM log2FC FDR
FOSL1::JUNB 118 (45.9%) 19.4 / 523.7 5.4 / 2.6 2.7e-03 / 1e-04
RBPJ 117 (45.5%) 295.7 1.8 7.3e-03
REL 96 (37.4%) 165.3 3 4.3e-06
FOSL2::JUNB 91 (35.4%) 81.2 / 523.7 2.4 / 2.6 1.2e-06 / 1e-04
IRF1 88 (34.2%) 1099.8 2.8 1.5e-04
RELA 87 (33.9%) 309 1.7 1e-06
JUNB 84 (32.7%) 523.7 2.6 1e-04
FOSL1 80 (31.1%) 19.4 5.4 2.7e-03
FOSL2 80 (31.1%) 81.2 2.4 1.2e-06
Nfe2l2 54 (21%) 684 1.5 2.4e-03
JDP2 53 (20.6%) 67.7 2.9 4.8e-04
NFKB2 28 (10.9%) 496.3 2.7 2.5e-04
Columns show TF motif name, number and percentage of overlapping enhancers among the induced enhancers, average expression of the corresponding TF(s) in
infected BMDM at 4 h, fold change and FDR of differentially expressed test for the corresponding TF(s) in infected BMDM at 4 h versus non-infected control at 0 h.
Motifs were retained for TFs with significant up-regulation at 4 h
Table 2 TF-mediated regulation of genes via induced enhancers
TF Motifs # overlapping enhancers # target DEGs
AP-1 (FOSL1::JUNB, FOSL2::JUNB, JUNB, FOSL2, FOSL1) 128 (49.8%) 180 (68.4%)
NF-kB (REL, RELA, NFKB2) 117 (45.5%) 157 (59.7%)
RBPJ 117 (45.5%) 160 (60.8%)
IRF1 88 (34.2%) 126 (47.9%)
Nfe2l2 54 (21%) 86 (32.7%)
JDP2 53 (20.6%) 92 (35%)
Total (12 motifs) 229 (89.1%) 250 (95.1%)
Columns show individual TF motifs or their groups, number and percentage of overlapping enhancers among the induced enhancers, number and percentage of
DEGs targeted by these enhancers among the 263 DEGs up-regulated at 4 h and associated with the induced enhancers
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demonstrated high specificity to the response of BMDM
to infection.
We further compared acquired enhancers to genomic re-
gions carrying H3K4me1 and H3K27ac histone marks,
which demarcate pre-established enhancer regions and ac-
tive enhancers, respectively. We used data from Ostuni et
al. [61] for untreated and LPS-treated macrophages. Of 356
acquired enhancers, 83.1 and 99.2% overlapped
H3K4me1-enriched regions in untreated and LPS-treated
macrophages, respectively, indicating that most acquired
transcribed enhancers might be established in naïve macro-
phages, prior to infection. Unexpectedly, as much as 63.8%
of acquired enhancers overlapped H3K27ac-enriched re-
gions in untreated macrophages. However, this percentage
was higher at 86% in LPS-treated macrophages, and the
corresponding H3K27ac ChIP-seq peaks were stronger
enriched in LPS-treated as compared to untreated macro-
phages (Additional file 18: Figure S12).
Acquired enhancers in the regulation of immune genes
during M.tb infection
The acquired enhancers in infected macrophages were
associated with 526 genes. The associated genes showed
an overall increased expression upon M.tb infection (Fig.
3c, right panel) and, importantly, a strong enrichment
for immune response-related functions (Fig. 3d). For fur-
ther analyses, we sub selected target DEGs that showed
up-regulation at 4 h post infection (251 genes, 47.7%,
Additional file 19: Table S7).
First, we investigated enhancer-gene associations and
found that, at maximum, a DEG was associated with six ac-
quired enhancers. We identified five such genes (Hivep1,
Fig. 3 Enhancers that acquire transcriptional activity de novo upon M.tb infection. a and (b) show presumable changes in gene regulation upon
infection: (a) In non-infected macrophages, a transcriptionally inactive enhancer loops towards its target gene, (b) Upon M.tb infection, the enhancer
acquires transcriptional activity; an additional loop is formed de novo for another acquired transcribed enhancer; the gene expression is induced. c
eRNA expression of 356 acquired enhancers (left) and their 526 target genes (right); dashed line shows median gene expression prior to the infection,
expression in TPM was averaged across replicates, p-values of Wilcoxon two-sided rank sum tests are shown. d Top 5 KEGG pathway maps with the
lowest FDR enriched for 526 target genes of the acquired enhancers; next to the bars are the numbers of genes in the KEGG term covered by our
gene list; dashed line indicates FDR = 0.05
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Itgb8, Pla2g4a, Ptgs2, and Tnfaip3). Among the genes,
Pla2g4a and Ptgs2 were co-regulated by the same set of ac-
quired enhancers within a TAD (Additional file 20: Figure
S13). Both genes are known to be involved in arachidonic
acid metabolism, one of the regulators of cell death, and to
play a role in infection responses [62]. While Pla2g4a
showed a moderate induction of log2FC = 2.9, expression of
Ptgs2 was induced dramatically with log2FC = 11.5 at 4 h
post infection (Additional file 20: Figure S13a), hinting at
its importance during infection.
The strongest induction of log2FC = 12.3 at 4 h was
observed for endothelin (Edn1), a DEG associated with
five acquired enhancers (Additional file 21: Figure S14).
Edn1 is a well-known vascular regulator; however, its
particular roles in infectious diseases including tubercu-
losis are only beginning to be elucidated [63]. Edn1 is
co-regulated with DEG Hivep1, a transcriptional regula-
tor for which the precise function in infected macro-
phages is unknown (Additional file 21: Figure S14).
All of Pla2g4a, Ptgs2, Edn1, and Hivep1 genes were add-
itionally associated with other enhancers, which were not
classified as acquired enhancers. Among those, Edn1 and
Hivep1 were associated with one enhancer that was
deemed induced in our study (Additional file 21: Figure
S14c), while Pla2g4a and Ptgs2 were associated with four
such induced enhancers (see Additional file 20: Figure
S13c for eRNA expression of one of them). These en-
hancers, in contrast to the acquired ones, showed nonzero
(although very low) eRNA expression in non-infected
macrophages. Notably, in infected macrophages these
induced enhancers had a higher expression than the
acquired enhancers associated to the same genes
(Additional file 20: Figure S13 and Additional file 21:
Figure S14). Thus, up-regulation of DEGs Pla2g4a, Ptgs2,
Edn1, and Hivep1 could not be attributed exclusively to
the activity of the acquired enhancers.
We further asked whether any of the 251 up-regulated
DEGs were associated exclusively with acquired en-
hancers. We identified 22 such genes regulated by a total
of 18 acquired enhancers. However, in most cases, we
observed either low or inconsistent eRNA expression
among replicates. Hence, our data could not reliably
infer up-regulated DEGs driven exclusively by acquired
enhancers. Moreover, the 251 DEGs were associated on
average with 1.6 acquired enhancers and 6.1 other en-
hancers, not classified as acquired. These findings sug-
gest that upon M.tb infection, de novo transcription at
enhancers targeting up-regulated DEGs is acquired in
addition to already established transcriptionally active
enhancers.
TF binding motif analysis of the acquired enhancers
showed overall similar results to that of the induced
enhancers, except for Irf1 motif which was
over-represented only in induced enhancers, and three
TF motifs over-represented only in acquired ones.
Among these, a motif for Stat3, a TF known to be in-
volved in M.tb infection response [64], overlaps 36.2% of
the acquired enhancers. Macrophage-restricted TF Tfec
with an overlap of 35.7% has been reported as an im-
portant regulator of IL-4 inducible genes in macro-
phages but was also up-regulated in response to LPS
treatment [65]. Finally, the Srebf2 motif overlaps 25.3%
of the acquired enhancers. Interestingly, this TF is a host
gene of miR-33, a miRNA induced in macrophages by
M.tb to inhibit pathways of autophagy, lysosomal func-
tion and fatty acid oxidation to support M.tb intracellu-
lar survival [66]. Taken together, these results uncover a
novel role of these TFs in the response to M.tb infection
in BMDM.
Discussion
Studies in multiple cell types unravelled the fundamental
importance of enhancer regions as DNA regulatory ele-
ments, however, our current understanding of these ele-
ments remains incomplete. High tissue specificity of
enhancers is a major hurdle towards establishing a com-
prehensive catalogue of the full enhancer population [9,
10]. Moreover, emerging evidence indicates that en-
hancers selectively act in a stimuli- or condition-specific
manner [19, 32]. Enhancers often mediate cell-type-spe-
cific processes [32]. Previously we reported on the role
of transcribed enhancers in macrophage activation and
polarisation towards pro- and anti-inflammatory pheno-
type [33]. Another recent study linked a specific class of
enhancers to the immune response in human [67].
Hence, we hypothesised that enhancers might also regu-
late macrophage response to the infection with intracel-
lular pathogens such as M.tb. To investigate this
possibility, here we analysed M.tb-induced changes of
gene expression and enhancer activity in macrophages.
Our results suggest that transcribed enhancers have a
strong influence in the infection response and mediate
up-regulation of many important immune protein-cod-
ing genes. The strongest macrophage response to M.tb
was observed at 4 h post infection, hence, we elected to
focus on DEGs up-regulated at this time point and to
analyse their associated enhancers. We characterised
highly transcriptionally induced enhancers and showed
that many genes acquired de novo transcribed enhancers
upon M.tb infection. We reported enhancers targeting
known immune genes crucial for the genetic response of
the host to M.tb and highlighted transcription factors
that are likely regulating these enhancers. These findings
were extended by highlighting particular chromosomal
domains carrying groups of highly transcriptionally in-
duced enhancers and genes with previously unappreci-
ated roles in M.tb infection.
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Previously we have demonstrated that regulation by
many enhancers was a concomitant of higher gene ex-
pression and tissue-specific functions [33], in agreement
with a model of additive enhancer action [8, 68]. Unex-
pectedly, here we report a similar observation for a
highly function-specific set of DEGs up-regulated upon
M.tb infection. Furthermore, our results indicate that ac-
tivation of SEs might have a prominent role in regulating
macrophage responses to the pathogen, in line with
current views of SEs as genomic regions of extreme im-
portance for the regulation of key genes involved in
cell-specific processes and responses [35, 36].
Several studies have reported on enhancers that were
activated de novo upon stimuli [61, 69]. These might
represent a particularly functionally important class of
enhancers responsible for establishing stimuli-specific
gene expression programmes. Ostuni et al. [61] uncov-
ered a set of latent enhancers that lacked any enhancer
characteristics in naïve mouse macrophages, but gained
active enhancer marks in response to stimulation. Simi-
larly, Kaikkonen et al. [69] identified enhancers activated
de novo in mouse macrophages stimulated with TLR4
agonist and, interestingly, suggested that eRNA tran-
scription might precede H3K4me1 deposition. In this
study, we asked whether any enhancers were
non-transcribed in naïve macrophages and acquired de
novo eRNA transcription upon M.tb infection. Interest-
ingly, in contrast to Ostuni et al. [61] and Kaikkonen et
al. [69], we found that most of the acquired enhancers
might be already marked with H3K4me1 (hence,
primed) in naïve macrophages. The remaining 60 of 356
enhancers might acquire both, a H3K4me1 mark and
transcriptional activity, upon infection. In agreement
with this idea, all 60 enhancers carried H3K4me1 his-
tone marks in LPS-treated macrophages. Moreover, we
found that 63.8% of acquired enhancers overlap
H3K27ac histone marks in untreated macrophages. This
is an unexpectedly large percentage, since H3K27ac is
believed to demarcate active enhancers. One possible ex-
planation is that H3K27ac-marked enhancers might have
a spectrum of activation states, including those with and
without eRNA production. In agreement with this hy-
pothesis, we observe a much stronger H3K27ac enrich-
ment in regions overlapping acquired enhancers in
LPS-treated as compared to untreated macrophages.
Hence, the strength of H3K27ac enrichment rather than
the presence or absence of this histone mark could de-
marcate actively transcribed enhancers.
Our findings indicate that up-regulated genes in
M.tb-infected macrophages might acquire de novo tran-
scribed enhancers in addition to already established ac-
tively transcribed enhancers. We hypothesise that
acquired enhancers might be involved in regulating their
target genes via at least two different mechanisms. First,
activation of acquired enhancers might involve consider-
able rearrangement of chromatin to allow formation of
novel DNA loops between enhancers and their target
promoters. Indeed, examples of stimuli-driven dynamical
changes in chromatin conformation in mouse macro-
phages were reported recently [70]. The second hypo-
thetical mechanism would involve the transcriptional
activation of enhancers within pre-established chromatin
loops. We found that acquired enhancers are often sur-
rounded by other enhancers that are transcribed in naïve
macrophages, including M.tb-induced enhancers. The
fact that these enhancers, at least in some cases, are lo-
cated close to each other and within SEs points to a
hypothetical regulatory mechanism that involves an ex-
pansion of active enhancer regions. For instance, a few
individual enhancers within a SE might be primed and
generate low levels of eRNAs in naïve macrophages.
Upon M.tb infection, these individual enhancers could
serve as ‘seeds’ to enable broader neighbouring regions
to acquire enhancer histone marks and stronger eRNA
transcription. Such a phenomenon has been described
in mouse stem cells, where seed enhancers were shown
to expand into SEs [71]. Similarly, a seed enhancer re-
quired for activation of a SE has been reported in mam-
mary glands [72]. However, the associated mechanisms
and abundances of such seed enhancers remain to be
elucidated.
We separately considered two overlapping subsets of
enhancers: acquired and induced enhancers. The identi-
fication was based on eRNA expression levels before and
after M.tb infection. However, it is important to note
that there is a narrow margin separating these classes,
which is influenced by the limits of expression versus
noise detection by CAGE and by our sample compos-
ition. In other settings, the composition of these classes
might differ from our results. For instance, some in-
duced enhancers showed very low (close to zero) eRNA
expression in non-infected macrophages, which could
be, alternatively, attributed to transcriptional noise.
Signalling pathways regulating macrophage responses
to infection have been extensively studied [1, 5, 73], and
here we report M.tb-induced enhancers that might acti-
vate these pathways. We find that induced enhancers
might extensively control Tnf and NF-κB signalling
pathways by targeting their components, starting from
receptors (Cd14 and Cd40) and ligands (Il1b, Tnfrsf1b,
Tnf ), through mediators (Traf5, Irak2, Jak2, Malt1,
Ripk2, and Src), ending with TFs (Nfkb1 and Rela) and
numerous pathway effectors. These pathways are known
to be activated upon macrophage recognition of M.tb
and play central roles in shaping immune responses, as
they mediate production of pro-inflammatory cytokines
and chemokines, and regulate apoptosis [74, 75]. Inter-
estingly, induced enhancers might also control negative
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feedback regulators of these pathways (Nfkbia, Tnfaip3,
and Socs3), which might implicate induced enhancers in
terminating immune responses.
As important examples, we highlighted genes regu-
lated by multiple induced or acquired enhancers. We
also reported on TADs, where induced enhancers were
over-represented, as these chromosomal regions could
be considerably affected by M.tb. Notably, in this man-
ner we highlighted a group of genes that might be de-
cisive in M.tb death versus survival balance via different
mechanisms. Knowledge on the regulation of these
genes is extremely important for understanding M.tb
survival strategies and development of novel treatments.
Genes with known immune functions are often
co-regulated with DEGs with previously unappreciated
functions in M.tb infection response (such as Fbxl3,
Tapt1, Edn1, and Hivep1), and these DEGs are, thus,
good candidates for further functional studies.
M.tb is known to control macrophage cell death path-
ways, and existing evidence suggests that M.tb might in-
duce necroptosis, which facilitates the spread of the
pathogen [76]. Here, we found that induced enhancers
might be involved in modulating macrophage cell death.
For instance, Tnf is targeted by three induced enhancers,
and might activate both apoptosis and necroptosis via
Tnf-signalling pathway, depending on expression of other
factors [76]. Activation of a DEG Tnfrsf1b, associated with
eight induced enhancers, is known to interfere with apop-
tosis and sensitise macrophages for Tnfr1-mediated
necroptosis [37, 38]. In addition, Pla2g4a, targeted by
four induced enhancers, is involved in metabolism of
arachidonic acid, a precursor of lipoxins, leukotrienes,
and prostaglandins, lipid mediators which regulate
apoptotic/necroptotic balance [62, 77]. Il1a and Il1b
DEGs, co-regulated by four induced enhancers, stimu-
late production of prostaglandins, linked to necropto-
sis suppression [77].
Finally, we investigated the transcriptional regulation
of induced and acquired enhancers. We identified TFs
with binding sites significantly over-represented in these
enhancer sets. Importantly, most of these TFs are known
to be activated in response to infection, for instance, via
Toll-like and Nod-like receptors upon recognition of the
pathogen. These findings propose a mechanistic link be-
tween M.tb infection and transcriptional activation of
enhancers that mediate up-regulation of immune genes.
Interestingly, we found that most of the TFBS motifs
over-represented in induced enhancers were also
over-represented in promoters of their target genes, in-
dicating co-regulation of enhancer and promoter tran-
scription by the same cellular machinery.
Macrophages are versatile immune cells, and a
spectrum of their phenotypes has been observed, includ-
ing distinct populations of tissue resident macrophages
[78]. In vivo, host alveolar macrophages, which are func-
tionally different from BMDM, are infected by M.tb.
While alveolar macrophages can be easily isolated from
mice, the yield is low for a full-scale transcriptomic ana-
lysis. In contrast, BMDMs can be expanded to large
numbers [79]. In addition, BMDM are greatly adherent,
homogenous and highly phagocytic [80]. Matured
BMDM easily respond to external cytokine stimulation
such as IFN-γ and can kill mycobacteria [81]. Although
there are some drawbacks of using BMDM as a model
system of infection in particular for drug efficacy studies
[82], the advantages have also been appealing to other
researchers, and BMDM have been used as the primary
macrophage model in many immunological transcrip-
tomic studies [79, 83–85]. However, as a consequence of
using naïve BMDM as a model, responses observed in
our data might differ from host alveolar macrophage
responses. Furthermore, some of the transcriptomic
changes analysed here could be triggered not by the
contact with M.tb per se, but rather by other M.tb
response-associated events, such as cytokine secretion.
Future studies of M.tb infection in combination with
cytokine stimulation could help to further characterise
this. In addition, the current study is limited by a miss-
ing independent validation of enhancer expression. This
could be facilitated in future studies by using for ex-
ample 5’RACE and ChIP-seq approaches in infected
macrophages.
One of the crucial areas of TB research is the develop-
ment of novel strategies for host-directed therapies, which
can stimulate host antimicrobial pathways and suppress
host subversion by M.tb [86, 87]. Targeting disease-specific
enhancers has been investigated as a therapeutic approach
in cancer and autoimmune diseases [88, 89]. This study
suggests that both acquired and induced enhancers regulate
immune genes, which are crucial for M.tb survival versus
elimination balance. Moreover, transcriptional activity of
these enhancers is characterised by a high macrophage-
and infection-specificity. Hence, these enhancers are likely
good candidate regulatory genomic regions for targeted
manipulation of macrophage responses toM.tb infection.
Conclusions
M.tb triggers extensive changes in macrophage gene ex-
pression programmes that are decisive for the infection
outcome, yet the associated regulatory mechanisms re-
main largely unknown. This is the first to our knowledge
study of the role of transcribed enhancers in macrophage
response to M.tb infection. It extends current understand-
ing of the regulation of M.tb responses by linking M.tb-re-
sponsive transcription factors to activation of transcribed
enhancers, which, in turn, target protein-coding immune
genes upon infection. Given the increasing promise for
enhancer- and chromatin-directed therapy, this work
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paves the way for further targeted studies towards a
host-directed therapy and novel tuberculosis treatments.
Methods
Bone marrow-derived macrophage (BMDM) generation
BALB/c mice were purchased from Jackson Laboratories
and bred at the Research Animal Facility, University of
Cape Town, South Africa. Mice were anaesthetized with
Xylazine (10 mg/kg) + Ketamine (100 mg/kg) via i.p. in-
jection in a total volume of 200 ul. Anaesthetized mice
were then sacrificed by cervical dislocation. BMDM were
generated from 8 to 12 week old male BALB/c mice as
described previously [90].
Ethics statement
Mice were sacrificed in accordance with the Animal Re-
search Ethics of South African National Standard (SANS
10386:2008) and University of Cape Town of practice for
laboratory animal procedures. The protocol (Permit
Number: 012/036) was approved by the Animal Ethics
Committee, Faculty of Health Sciences, University of
Cape Town, Cape Town, South Africa.
M.tb infection
BMDM were plated in 6-well plates (Nunc, Denmark) at
2 × 106 cells per well and left to adhere for 40 h. BMDM
were then infected with log phase M.tb HN878 (MOI =
5) for 4 h. The choice of MOI was defined by the fact
that at a higher MOI (10:1), BMDM died at the late
stage of infection with HN878 (120 h post infection). At
lower MOI (1:1) not all BMDM were infected creating a
heterogeneous population consisting of un-infected and
M.tb-infected BMDM. Therefore, we have opted for a
MOI of (5:1) to enable a homogenous population of in-
fected BMDM. This is in line with former studies on
transcriptional response of BMDM infected with M.tb
HN878, where the same MOI of (5:1) was utilized [91].
Cells were washed to remove extracellular mycobac-
teria and replenished with fresh medium containing
10 μg/ml of gentamycin. At 0, 4, 12, 24 and 48 h,
M.tb-infected and non-infected BMDM were lysed with
700 μl of Qiazol (Qiagen, Valencia, CA, USA) for RNA
extraction. Total RNA was prepared using miRNAeasy
kit (Qiagen, Valencia, CA, USA) and concentration and
quality of each RNA samples was verified as described
previously [90]. All M.tb infection experiments were per-
formed at the Biosafety Level 3 (BSL-3) laboratory, Insti-
tute of Infectious Disease and Molecular Medicine
(IDM), University of Cape Town, South Africa.
Data
Macrophage samples were profiled by us using cap ana-
lysis of gene expression (CAGE) as described in Roy et
al. [92]. Samples used in this study include three
biological replicates per time point profiled at 4, 12, 24,
and 48 h post infection in M.tb HN878-infected and
control macrophages (except for 48 h infected samples,
where two biological replicates were available). In
addition, four biological replicates were profiled prior to
infection at 0 h and six more samples were profiled dur-
ing macrophage cultivation before this time point.
Mouse genome assembly mm10 and Ensembl gene
models version 75 were used [93]. CAGE-derived tag
counts were normalized to tags per million (TPM) using
TMM normalization [94].
Data were processed, including identification of en-
hancer regions and enhancer-gene associations, as de-
scribed in Denisenko et al. [33]. Briefly, enhancers were
defined following the strategy of Andersson et al. [17] as
bidirectionally transcribed 401 bp regions, and further
were required to overlap ChIP-seq-derived H3K4me1
histone marks [61]. Enhancer-gene associations were
established by selecting enhancers and promoters which
were located within the same TAD [28] and showed
positive Spearman’s correlation coefficient of expression
in macrophages with FDR < 10− 4 (Benjamini-Hochberg
procedure [95]). Of all enhancer-gene associations estab-
lished in [33], we here sub selected only those with a
positive Spearman’s correlation of expression specifically
in the infected macrophage samples.
Differential expression analysis
Differential gene expression analyses were performed
using the exact test implemented in edgeR [94]. Four
macrophage samples profiled prior to the infection (0 h)
were used as a control. The p-values were adjusted for
multiple hypothesis testing using the Benjamini-Hoch-
berg procedure [95]. FDR ≤ 0.05 and log2 fold change > 1
(< − 1) thresholds were used to select differentially
expressed up- (down-) regulated genes (DEGs).
Gene set enrichment analysis (GSEA)
KEGG pathway maps [96] were used as a set of bio-
logical terms for GSEA. We used the hypergeometric
distribution to calculate the probability of obtaining the
same or larger overlap between a gene set of interest
and each biological term [97]. Derived p-values were
corrected for multiple testing using Benjamini-Hochberg
procedure [95]. As a background gene list, a set of
22,543 Ensembl protein-coding genes (version 75) was
used [93].
Overlaps with ChIP-seq data
We used ChIP-seq data for H3K4me1 and H3K27ac his-
tone marks profiled in untreated and LPS-treated mac-
rophages by Ostuni et al. [61] (Gene Expression
Omnibus accession GSE38379). Genomic coordinates of
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significant ChIP-seq peaks were converted from mm9 to
mm10 using the liftOver program [98].
Transcription factor binding analysis
Transcription factor (TF) binding profiles were down-
loaded from JASPAR database, 7th release, 2018 [99].
The Clover program [100] was used for identification of
statistically over-represented motifs. Enhancer regions
were tested against three background DNA sets, as pre-
viously defined by us [33]: 1) the whole set of tran-
scribed mouse enhancers; 2) a subset of these enhancers
not transcribed in macrophages; 3) a set of random gen-
omic regions excluding gaps, repeated sequences,
Ensembl coding regions, and the transcribed mouse en-
hancers. Promoter regions were tested against the fol-
lowing three sets: 1) all promoters expressed in mouse
tissues; 2) a subset of those not expressed in macro-
phages; 3) the same set of random genomic regions as
used for enhancers. Promoters were used as defined in
[33] and were extended by 500 bp upstream and down-
stream. Motifs with p-value < 0.01 for each of the three
background sets were selected as significantly
over-represented. TFs that were significantly differen-
tially expressed and up-regulated at 4 h post infection
when compared to 0 h were retained.
M.tb-induced and acquired enhancers
M.tb-induced enhancers were selected among those as-
sociated with DEGs up-regulated at 4 h post infection.
Mean eRNA expression for these enhancers at 4 h and
its fold change compared to 0 h were calculated. En-
hancers were defined as induced, if both these values
were in the upper quartiles of their corresponding
distributions. Acquired enhancers were defined as those
with no detectable eRNA expression in each of 22
non-infected BMDM samples, and nonzero expression
in any of the infected macrophage samples.
TADs enriched for enhancers
Genomic coordinates of TADs in mouse embryonic stem
cells were obtained from a study by Dixon et al. [28] and
were converted from mm9 to mm10 using the liftOver
program [98]. To uncover chromosomal domains that
might be important in macrophage response to M.tb, we
identified TADs that were significantly enriched for in-
duced enhancers. A hypergeometric test was performed
for each TAD by comparing the total number of BMDM
enhancers in that TAD to the subset of those deemed in-
duced. The p-values for 1228 TADs were corrected for
multiple hypothesis testing using Benjamini-Hochberg
procedure [95]. TADs with FDR < 0.05 were selected as
significantly enriched for induced enhancers.
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